nAscent BioSciences Inc.
101 Rogers Street, Suite 216
6 articles with nAscent BioSciences Inc.
6/26/2020Biopharma and life sciences companies bolster their executive teams and board with these Movers & Shakers.
Nascent Biotech, Inc. (OTC: NBIO) announced today that it has appointed Dr. Navpaul Singh MD as Chief Medical Consultant in charge of research into Pritumumab’s use with viral infections, including COVID-19. Dr. Singh stated, “With the present pandemic, the need for further research is essential to both understand and inhibit COVID-19’s continual spread. This opportunity with Nascent Biotech allows me to continue my medical work in viral infectio
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 24, 2020.
Nascent Biotech, Inc. (OTCQB: NBIO) , today announced after receiving early In-Vitro study results Pritumumab, (PTB), will be advanced to laboratory-based animal studies. Nascent founder and Advisory Board Chairman Dr. Mark Glassy commented, “The laboratory results were consistent with our Brain Cancer in vitro studies and this is the next step in investigational development of PTB as potential use with COVID-19 and related Viral Infections.” An
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 12, 2020.